Zobrazeno 1 - 10
of 35
pro vyhledávání: '"J. Geldof"'
Autor:
E. Gökce, J. Geldof, P. Roelandt, J. Van Dorpe, S. Callens, D. De Looze, S. Hoeck, P. Martens, R. Van Damme, A.-S. Van Parys, C. Vogels, K. Roelens, G. Lemmens, Z. Claesen, A. Ravelingien, K. Solhdju, P. Borry, H. Van Poppel, B. Vansevenant, S. Collen, M. Finoulst, P. Vankrunkelsven, P. Calle
Publikováno v:
Tijdschrift voor Geneeskunde.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b5b1c033842dcb871c9f07cd8c02ea1
https://doi.org/10.47671/tvg.78.22.e021
https://doi.org/10.47671/tvg.78.22.e021
Publikováno v:
Tijdschrift voor Geneeskunde.
Early detection of precursor lesions of anal cancer in HIV-seropositive patients Although anal cancer is rare in the overall population, its incidence is increasing in the last decades. Especially HIV-seropositive patients have an increased risk of d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37abcd2b07f92ec153e0e4fed67de59b
https://doi.org/10.47671/tvg.77.21.129
https://doi.org/10.47671/tvg.77.21.129
Autor:
J Geldof, N Iqbal, J F LeBlanc, R Sawyer, C Buskens, W Bemelman, K Gecse, L Lundby, A L Lightner, S Danese, A Spinelli, M Carvello, O Faiz, J Warusavitarne, P Lung, D De Looze, A D’Hoore, S Vermeire, A Hart, P Tozer
Publikováno v:
Journal of Crohn's and Colitis. 16:i021-i022
Background Perianal fistulising Crohn’s disease (CD) is an aggressive disease phenotype that can have a significant impact on patients’ quality of life. Current biological understanding of perianal fistulising CD remains inadequate and previous c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::037c19dba93b14abb7817b5f6f42c3e4
https://doi.org/10.1093/ecco-jcc/jjab232.018
https://doi.org/10.1093/ecco-jcc/jjab232.018
Autor:
J Geldof, J Sabino, M Ferrante, J Lambert, H Lapeere, T Hillary, A Van Laethem, K De Vlam, P Verschueren, T Lobaton, S Vermeire
Publikováno v:
Journal of Crohn's and Colitis. 16:i482-i483
Background Immunomodulators (IMM) and Targeted Immune-Modulating Therapies (TIMT) such as anti-TNF, anti-interleukins and Janus Kinase inhibitors, for treatment of Immune Mediated Inflammatory diseases (IMID) could theoretically interfere with the cy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc0b263737155f2cbbf8e0988f21fe33
https://doi.org/10.1093/ecco-jcc/jjab232.656
https://doi.org/10.1093/ecco-jcc/jjab232.656
Publikováno v:
Journal of Crohn's and Colitis. 16:i315-i316
Background Infliximab (IFX) is effective in treatment of inflammatory bowel disease (IBD). However, primary non-response and secondary loss-of-response rates go up to 30–40% and intolerance may occur leading to treatment switch. Unfortunately, even
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74ba03a2979a247baf18414dbff27901
https://doi.org/10.1093/ecco-jcc/jjab232.410
https://doi.org/10.1093/ecco-jcc/jjab232.410
Autor:
Tom Hillary, F. Castelijns, A. Van Laethem, João Sabino, K. de Vlam, Marc Ferrante, Severine Vermeire, Jo Lambert, J. Geldof, Patrick Verschueren, Hilde Lapeere, T. Lobaton
Publikováno v:
The Journal of Investigative Dermatology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::247b6fd39c8e45aaa0c3bec9e11c99f0
http://europepmc.org/articles/PMC8497030
http://europepmc.org/articles/PMC8497030
Publikováno v:
Journal of Crohn's and Colitis. 14:S488-S489
Background Treatment of Crohn’s disease (CD) involves medications and surgery but experiencing medication side effects (SE) limits medical options. The aim of this study was to compare SE experienced by patients with CD and intestinal failure (CD-I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::949004f577ca44e4c257fca524c064c6
https://doi.org/10.1093/ecco-jcc/jjz203.711
https://doi.org/10.1093/ecco-jcc/jjz203.711
Publikováno v:
Journal of Crohn's and Colitis. 14:S591-S592
Background Intestinal failure (IF) is an uncommon complication of severe Crohn’s disease (CD) due to extensive or recurrent resections or complications. It is observed that disease activity might remit once IF develops. This is unexpected given the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2efe85406637e046589170b5ae2b1494
https://doi.org/10.1093/ecco-jcc/jjz203.867
https://doi.org/10.1093/ecco-jcc/jjz203.867
Autor:
A. Van Laethem, Marc Ferrante, Belcomid, Tom Hillary, K. de Vlam, Jo Lambert, Severine Vermeire, João Sabino, J. Geldof, Patrick Verschueren, M Truyens, T Lobaton, H Lapeere
Publikováno v:
Journal of Crohn's & Colitis
Background It has been suggested that 100% of SARS-CoV2 infections leads to development of specific IgG antibodies that remain detectable for a long period of time. Targeted Immune-Modulating Therapies (TIMT) such as anti-TNF, anti-interleukins and J
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d5d1611faf24652275278d80783ca03
https://doi.org/10.1093/ecco-jcc/jjab076.564
https://doi.org/10.1093/ecco-jcc/jjab076.564
Publikováno v:
Journal of Crohn's and Colitis. 14:S462-S462
Background In 2016, the top 10 research priorities in treatment of inflammatory bowel diseases (IBD) were outlined by a group of clinicians, patients and patient-support organisations based in the UK, using the infrastructure of the James Lind Allian
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b73a7a6678294b25668880b3f6ef639
https://doi.org/10.1093/ecco-jcc/jjz203.669
https://doi.org/10.1093/ecco-jcc/jjz203.669